B. Riley Names Top Digital Health Stock to Buy By Investing.com
B. Riley Securities reiterated LifeMD Inc. as its top digital health pick after its 26th Annual Institutional Investor Conference. The firm rates LFMD Buy, with a $10 price target, citing a telehealth collaboration with Antares for XYOSTED, Medicare GLP-1 coverage via Humana, and potential FDA compounding changes. It also cites LifeMD Q1 2026 revenue of $50.2M and EPS of -$0.20.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the event calendar (Medicare coverage ramp and July 23-24 FDA committee) combined with an analyst reiteration and target, which can influence positioning and options sentiment even if it is not a new fundamental disclosure.
Market read
The article can support bullish positioning in LFMD into late-July FDA review and the Medicare GLP-1 ramp, but it is mostly an analyst catalyst recap with limited new, verifiable disclosures in the text.
What to watch
Execution risk in capturing branded pharmacy economics, competitive pressure from larger GLP-1 ecosystem players, and uncertainty around FDA committee outcomes for the 503A bulks list.
Background
B. Riley highlights LifeMD’s telehealth model and reimbursement-linked growth path after a sell-off, using Medicare GLP-1 coverage, an Antares collaboration, and an FDA compounding agenda as the catalyst framework.
Ticker impact
B. Riley reiterates LifeMD as its top digital health pick, citing a new Antares telehealth collaboration, Medicare GLP-1 coverage, and July 23-24 FDA compounding review.
Near-term sentiment could stay supported if traders treat the Medicare GLP-1 and FDA compounding agenda as incremental demand catalysts, but follow-through depends on actual execution and any subsequent company filings.
Key items (Medicare GLP-1 bridge, FDA committee dates, and the Antares collaboration) are framed as catalysts, yet the only explicit new company-specific datapoint is that LifeMD “announced” Q1 2026 results and appointed a CTO, which may already be known by the time of publication.
Market effects
Reinforces the digital health and telehealth-adjacent narrative tied to reimbursement expansion for GLP-1 obesity drugs and potential margin capture via branded pharmacy economics.
No clear regional-specific impact beyond US Medicare reimbursement and US FDA agenda.
Limited, as catalysts cited are US Medicare and FDA-related.
Counterpoint
The catalysts are largely agenda and thesis-driven (analyst framing), so the market may already price them, leaving limited incremental upside without hard execution milestones from LifeMD.
Key entities
- companyLifeMD Inc.
Digital health telehealth company highlighted as B. Riley’s top pick, with catalysts tied to Medicare GLP-1 coverage and pharmacy compounding review.
- companyAntares
Partner referenced for an exclusive telehealth collaboration tied to a direct-to-patient XYOSTED program.
- companyHumana
Named as the central processor for Medicare GLP-1 coverage for specified products under CMS guidance.
- companyNovo Nordisk
Referenced for potential next-generation GLP-1 launches, including CagriSema timing.
- companyEli Lilly
Referenced for potential next-generation GLP-1 launches, including retatrutide timing.
